JP2022508609A5 - - Google Patents

Info

Publication number
JP2022508609A5
JP2022508609A5 JP2021543970A JP2021543970A JP2022508609A5 JP 2022508609 A5 JP2022508609 A5 JP 2022508609A5 JP 2021543970 A JP2021543970 A JP 2021543970A JP 2021543970 A JP2021543970 A JP 2021543970A JP 2022508609 A5 JP2022508609 A5 JP 2022508609A5
Authority
JP
Japan
Prior art keywords
hypertonic solution
composition
solution according
interstitium
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543970A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611149B2 (ja
JP2022508609A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053808 external-priority patent/WO2020072357A1/en
Publication of JP2022508609A publication Critical patent/JP2022508609A/ja
Publication of JP2022508609A5 publication Critical patent/JP2022508609A5/ja
Priority to JP2024064529A priority Critical patent/JP2024099600A/ja
Application granted granted Critical
Publication of JP7611149B2 publication Critical patent/JP7611149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543970A 2018-10-04 2019-09-30 血漿浸透圧を操作することによるグリンパティック送達の改善 Active JP7611149B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024064529A JP2024099600A (ja) 2018-10-04 2024-04-12 血漿浸透圧を操作することによるグリンパティック送達の改善

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741295P 2018-10-04 2018-10-04
US62/741,295 2018-10-04
PCT/US2019/053808 WO2020072357A1 (en) 2018-10-04 2019-09-30 Improvement of glymphatic delivery by manipulating plasma osmolarity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024064529A Division JP2024099600A (ja) 2018-10-04 2024-04-12 血漿浸透圧を操作することによるグリンパティック送達の改善

Publications (3)

Publication Number Publication Date
JP2022508609A JP2022508609A (ja) 2022-01-19
JP2022508609A5 true JP2022508609A5 (enExample) 2022-06-08
JP7611149B2 JP7611149B2 (ja) 2025-01-09

Family

ID=68502006

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543970A Active JP7611149B2 (ja) 2018-10-04 2019-09-30 血漿浸透圧を操作することによるグリンパティック送達の改善
JP2024064529A Withdrawn JP2024099600A (ja) 2018-10-04 2024-04-12 血漿浸透圧を操作することによるグリンパティック送達の改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024064529A Withdrawn JP2024099600A (ja) 2018-10-04 2024-04-12 血漿浸透圧を操作することによるグリンパティック送達の改善

Country Status (8)

Country Link
US (1) US12311035B2 (enExample)
EP (1) EP3860564A1 (enExample)
JP (2) JP7611149B2 (enExample)
KR (1) KR20210100086A (enExample)
CN (1) CN113226283A (enExample)
AU (1) AU2019354965B2 (enExample)
CA (1) CA3115071A1 (enExample)
WO (1) WO2020072357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4175698A4 (en) * 2020-08-03 2024-07-31 Transluminal Systems, LLC DEVICES AND METHODS FOR ARTERIAL OSMOTIC EMBOLIZATION OF PATHOLOGICAL TISSUES
US20250235554A1 (en) * 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux
US12483569B2 (en) 2024-03-28 2025-11-25 Bank Of America Corporation System and method for identifying unauthorized data traffic in a computing network
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
DE69636937T3 (de) 1995-12-15 2011-01-05 Virxsys Corp. Durch trans-spaltung erhaltene therapeutische molekule
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005500389A (ja) 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8801541B2 (en) 2007-09-27 2014-08-12 Taylor Made Golf Company, Inc. Golf club
WO2006014638A2 (en) * 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
EP1799260A4 (en) 2004-09-29 2011-09-28 Centocor Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
BR112012000908A2 (pt) 2009-07-14 2019-09-24 Mayo Found Medical Education & Res liberação de agentes ativos através da barreira hematoencefálica mediada por peptídeo em associação não covalente
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
JP6382232B2 (ja) * 2013-02-21 2018-08-29 ユニバ−シティ オブ ロチェスタ− 脳全体の傍血管経路を老廃物のクリアランス機能について評価するための方法、およびそれに基づいて神経変性障害を治療するための方法
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
JP6824535B2 (ja) 2015-09-11 2021-02-03 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳間質内のナノ粒子分布を改善するための組成物および方法
US10123969B2 (en) * 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
AU2017207818B2 (en) * 2016-01-15 2024-03-28 Regents Of The University Of Minnesota Methods and compositions for the treatment of neurologic disease
WO2017210343A1 (en) * 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
US20190282792A1 (en) * 2016-07-20 2019-09-19 P&X Medical Nv Compounds for use in methods for treating glaucoma and retinal diseases
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides

Similar Documents

Publication Publication Date Title
Hernandez et al. Liposome based drug delivery as a potential treatment option for Alzheimer's disease
US12496345B2 (en) Method of treating cancer
Han et al. Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies
Talegaonkar et al. Intranasal delivery: An approach to bypass the blood brain barrier
JP2006516116A5 (enExample)
US20210069354A1 (en) Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
JP2019524865A5 (enExample)
JP2015520188A5 (enExample)
JP2020532958A5 (enExample)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2019531293A5 (enExample)
RU2002115406A (ru) Соединение, обладающее свойствами высвобождения гормона роста
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
Ye et al. Macrophages as nanocarriers for drug delivery: novel therapeutics for central nervous system diseases
EP4548924A3 (en) Enhanced delivery of drugs and other compounds to the brain and other tissues
US11065273B2 (en) Treatment and prevention of alzheimer's disease (AD)
JP2009542609A5 (enExample)
JP2009523819A (ja) 筋萎縮性側索硬化症のための脳室内タンパク質送達
JP2020503318A5 (enExample)
JP2024518426A5 (enExample)
JP2022551105A5 (enExample)
Rajkonwar et al. Blood–Brain Barrier as a Point of Concern for Neural Drug Delivery: Problems and Advancements
Sharma et al. Unravelling Nanotherapeutics for Treatment of Neuroinfectious Diseases
Parra et al. Perspectives of Nanoscience and Nanotechnology in Medicine and Pharmacy
Mamada et al. Brain Diseases: An Introduction and the Need for Novel Drug-Delivery Approaches